Literature DB >> 25037794

Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study.

Lorinda Chung1, Katharine Ball2, Aaliya Yaqub3, Bharathi Lingala4, David Fiorentino2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25037794      PMCID： PMC4356009          DOI： 10.1016/j.jaad.2014.04.028

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

2.  Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study.

Authors:  Simone Parisi; Clara L Peroni; Angela Laganà; Marco Scarati; Federico Ambrogio; Maria Bruzzone; Enrico Fusaro
Journal:  Rheumatology (Oxford)       Date:  2013-03-05       Impact factor: 7.580

3.  Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.

Authors:  Janet J Maguire; Rhoda E Kuc; Anthony P Davenport
Journal:  Life Sci       Date:  2012-05-23       Impact factor: 5.037

4.  Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.

Authors:  Marco Matucci-Cerinic; Christopher P Denton; Daniel E Furst; Maureen D Mayes; Vivien M Hsu; Patrick Carpentier; Fredrick M Wigley; Carol M Black; Barri J Fessler; Peter A Merkel; Janet E Pope; Nadera J Sweiss; Mittie K Doyle; Bernhard Hellmich; Thomas A Medsger; Adele Morganti; Fabrice Kramer; Joseph H Korn; James R Seibold
Journal:  Ann Rheum Dis       Date:  2010-08-30       Impact factor: 19.103
  4 in total
  6 in total

Review 1.  Functional autoantibodies in systemic sclerosis.

Authors:  Jeannine Günther; Judith Rademacher; Jakob M van Laar; Elise Siegert; Gabriela Riemekasten
Journal:  Semin Immunopathol       Date:  2015-08-21       Impact factor: 9.623

Review 2.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

Review 3.  Drugs in phase I and phase II clinical trials for systemic sclerosis.

Authors:  Melody P Chung; Lorinda Chung
Journal:  Expert Opin Investig Drugs       Date:  2020-03-25       Impact factor: 6.206

4.  Pharmacotherapy Options in the Management of Raynaud's Phenomenon.

Authors:  Alicia M Hinze; Fredrick M Wigley
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-07-04

5.  Microvascular Hand Surgery for Digital Ischemia in Scleroderma.

Authors:  Ellen S Satteson; Melody P Chung; Lorinda S Chung; James Chang
Journal:  J Scleroderma Relat Disord       Date:  2019-06-29

6.  Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.

Authors:  Christopher P Denton; Éric Hachulla; Gabriela Riemekasten; Andreas Schwarting; Jean-Marie Frenoux; Aline Frey; Franck-Olivier Le Brun; Ariane L Herrick
Journal:  Arthritis Rheumatol       Date:  2017-12       Impact factor: 10.995
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.